{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1361137045360424320.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1016/j.vaccine.2005.06.024"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S0264410X05006353?httpAccept=text/xml"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S0264410X05006353?httpAccept=text/plain"}}],"dc:title":[{"@value":"TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848)"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1381137045360424322","@type":"Researcher","foaf:name":[{"@value":"Risini D. Weeratna"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137045360424321","@type":"Researcher","foaf:name":[{"@value":"Shawn R. Makinen"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137045360424320","@type":"Researcher","foaf:name":[{"@value":"Michael J. McCluskie"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137045360424323","@type":"Researcher","foaf:name":[{"@value":"Heather L. Davis"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"0264410X"}],"prism:publicationName":[{"@value":"Vaccine"}],"dc:publisher":[{"@value":"Elsevier BV"}],"prism:publicationDate":"2005-11","prism:volume":"23","prism:number":"45","prism:startingPage":"5263","prism:endingPage":"5270"},"reviewed":"false","dc:rights":["https://www.elsevier.com/tdm/userlicense/1.0/"],"url":[{"@id":"https://api.elsevier.com/content/article/PII:S0264410X05006353?httpAccept=text/xml"},{"@id":"https://api.elsevier.com/content/article/PII:S0264410X05006353?httpAccept=text/plain"}],"createdAt":"2005-07-19","modifiedAt":"2023-05-03","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360004236842912896","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Attachment of class B CpG ODN onto DOTAP/DC-chol liposome in nasal vaccine formulations augments antigen-specific immune responses in mice"}]},{"@id":"https://cir.nii.ac.jp/crid/1360021389807232896","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"TLR agonists as vaccine adjuvants in the prevention of viral infections: an overview"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565165991025536","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Zymosan Induces Immune Responses Comparable with Those of Adults in Monocytes, Dendritic Cells, and Monocyte-Derived Dendritic Cells from Cord Blood"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1016/j.vaccine.2005.06.024"},{"@type":"CROSSREF","@value":"10.1186/s13104-017-2380-8_references_DOI_Jz5XLLdvNpwSlhRt5KTBXvh1wb9"},{"@type":"CROSSREF","@value":"10.3389/fmicb.2023.1249718_references_DOI_Jz5XLLdvNpwSlhRt5KTBXvh1wb9"},{"@type":"CROSSREF","@value":"10.1016/j.jpeds.2015.03.035_references_DOI_Jz5XLLdvNpwSlhRt5KTBXvh1wb9"}]}